Literature DB >> 28086201

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

Mark M Smits1, Lennart Tonneijck2, Marcel H A Muskiet2, Trynke Hoekstra3, Mark H H Kramer2, Michaela Diamant2, Daniël H van Raalte2.   

Abstract

AIMS: To assess the effects of glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors on postprandial haemodynamics.
METHODS: 57 patients with type 2 diabetes (mean±SD age 62.8±6.9years; BMI 31.8±4.1kg/m2; HbA1c 7.3±0.6%) were included in an acute (exenatide- or placebo-infusion) and 12-week (liraglutide, sitagliptin or placebo) randomised, placebo-controlled, double-blind trial. Systemic haemodynamics (oscillometric technique and finger photoplethysmography), vascular stiffness (tonometry), and sympathetic nervous system (SNS)-activity (heart rate variability) were determined in the fasting state and following a standardised mixed meal.
RESULTS: In both studies, postprandial blood pressure (BP) decreased during placebo-intervention. Compared with placebo, acute exenatide-infusion increased postprandial diastolic BP (6.7 [95%-confidence interval 3.6-9.9]mmHg, p<0.001) and vascular resistance (683.6 [438.5-928.8]dyn*s/cm5/1.73m2, p<0.001), while cardiac index decreased (0.6 [0.40.8]L/min/1.73m2; p<0.001). Systolic BP, augmentation index and SNS-activity were unaffected. Twelve-week liraglutide-treatment did not affect postprandial haemodynamics, while sitagliptin decreased diastolic BP (3.5 [0.0-6.9] mmHg; p=0.050), vascular resistance (309.9 [66.6-553.1]dyn*s/cm5/1.73m2; p=0.013) and cardiac index (0.3 [0.0-0.6]L/min/1.73m2; p=0.040), compared with placebo. Neither liraglutide nor sitagliptin affected SNS-activity or augmentation index. All treatments significantly lowered postprandial glucose levels.
CONCLUSIONS: Acute exenatide-infusion prevented the meal-induced decline in diastolic BP, although prolonged liraglutide intervention did not affect postprandial haemodynamics. The meal-induced drop in BP was augmented during sitagliptin-treatment.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Exenatide; GLP-1 receptor agonist; Haemodynamics; Heart rate; Liraglutide; Sympathetic nervous system

Mesh:

Substances:

Year:  2016        PMID: 28086201     DOI: 10.1016/j.diabres.2016.12.011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

Review 1.  Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease.

Authors:  Petter Bjornstad; David Z Cherney
Journal:  Curr Diab Rep       Date:  2018-03-19       Impact factor: 4.810

2.  Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.

Authors:  Vaia Lambadiari; George Pavlidis; Foteini Kousathana; Maria Varoudi; Dimitrios Vlastos; Eirini Maratou; Dimitrios Georgiou; Ioanna Andreadou; John Parissis; Helen Triantafyllidi; John Lekakis; Efstathios Iliodromitis; George Dimitriadis; Ignatios Ikonomidis
Journal:  Cardiovasc Diabetol       Date:  2018-01-08       Impact factor: 9.951

3.  α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.

Authors:  Michio Shimabukuro; Atsushi Tanaka; Masataka Sata; Kazuoki Dai; Yoshisato Shibata; Yohei Inoue; Hiroki Ikenaga; Shinji Kishimoto; Kozue Ogasawara; Akira Takashima; Toshiyuki Niki; Osamu Arasaki; Koichi Oshiro; Yutaka Mori; Masaharu Ishihara; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2017-07-06       Impact factor: 9.951

Review 4.  The Origin and Understanding of the Incretin Concept.

Authors:  Jens F Rehfeld
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-16       Impact factor: 5.555

Review 5.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

6.  Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.

Authors:  Jordan Kraaijenhof; Marcel H A Muskiet; Lennart Tonneijck; D Margriet Ouwens; Mark H H Kramer; Daniël H van Raalte; Mark M Smits
Journal:  Diabetes Obes Metab       Date:  2020-06-22       Impact factor: 6.577

7.  Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis.

Authors:  Biqing Wang; Junnan Zhao; Qiuxiao Zhan; Rongyanqi Wang; Birong Liu; Yan Zhou; Fengqin Xu
Journal:  Front Cardiovasc Med       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.